Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724167 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNAHPGDKMT2A | |
| SCHEMBL13101500 | 0.84 | MAPT (0.62) | ALDH1A1MAPTLMNAKMT2AHTT | |
| SCHEMBL420503 | 0.82 | CTSK (0.51) | ALDH1A1CTSKNPC1KMT2AHTT | |
| SCHEMBL4924522 | 0.80 | MEN1 (0.48) | ALDH1A1CTSKNPC1KMT2AHTT | |
| SCHEMBL15827736 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNANPC1KMT2A | |
| SCHEMBL10151442 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNANPC1KMT2A | |
| SCHEMBL9044759 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MAPTHTTHTR2ARAB9A | |
| SCHEMBL8587397 | 0.77 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAHPGDNPC1 | |
| SCHEMBL9519331 | 0.77 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAHPGDNPC1 | |
| SCHEMBL10151482 | 0.76 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAHTR2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281686-A1 | Aza-peptides | LABORATOIRES SERONO SA (CH) | 2006-12-14 | — | — | US | disclosed |
| EP-1567546-A2 | AZA-PEPTIDES | Applied Research Systems ARS Holding N.V. (AN) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050689-A2 | AZA-PEPTIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281686-A1 | Aza-peptides | APP, APBA1, IAPP | ALDH1A1 4161/4885MAPT 302/4885LMNA 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.